

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph of the application on page 8, lines 6-7 with the following:

-- Z is C(=O)GR² or C(H)₂GR²; CT¹T²-G-R² where T¹ and T² are independently selected from H, alkyl or substituted alkyl or T¹ and T² are taken together to form O, and G is alkyl, O or NH or none, or when Z is C(=O)GR², G also includes 1, 2 propylene;--

Please replace the paragraph of the application on page 10, lines 1-2 with the following:

-- Z is C(=O)GR² or C(H)₂GR²; CT¹T²-G-R² where T¹ and T² are independently selected from H, alkyl or substituted alkyl or T¹ and T² are taken together to form O, and G is alkyl, O or NH or none, or when Z is C(=O)GR², G also includes 1, 2 propylene;--

Please replace the paragraph in the Abstract of the Disclosure on page 59, lines 1-2 with the following:

-- Z is C(=O)GR² or C(H)₂GR²; CT¹T²-G-R² where T¹ and T² are independently selected from H, alkyl or substituted alkyl or T¹ and T² are taken together to form O, and G is alkyl, O or NH or none, or when Z is C(=O)GR², G also includes 1, 2 propylene;--

Please replace the paragraph on page 48, lines 3-9 with the following:

-- The biological activity of the compounds of the invention has been measured using the CEM binding assay described above. The range of activity was measured was over an IC₅₀ value range of 5 nm to 100 uM. The compounds disclosed herein are capable of binding to chemokine receptors at a measurable level, using the above-described assay or an assay which can determine the binding activity to chemokine receptors.--